Co-Authors
This is a "connection" page, showing publications co-authored by MARK J ROUTBORT and L JEFFREY MEDEIROS.
Connection Strength
3.579
-
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers (Basel). 2020 Jul 14; 12(7).
Score: 0.185
-
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
Score: 0.170
-
Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection. J Mol Diagn. 2019 01; 21(1):89-98.
Score: 0.166
-
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
Score: 0.165
-
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
Score: 0.138
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.127
-
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012 Mar 15; 118(6):1566-73.
Score: 0.100
-
Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008 Sep; 32(9):1299-309.
Score: 0.081
-
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024 Oct; 99(10):1959-1968.
Score: 0.061
-
STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
Score: 0.060
-
Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization. Cancer Cytopathol. 2024 Jan; 132(1):41-49.
Score: 0.058
-
DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
Score: 0.056
-
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel). 2022 Dec 21; 12(1).
Score: 0.055
-
Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel). 2022 Sep 20; 14(19).
Score: 0.054
-
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
Score: 0.053
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.053
-
Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 May; 35(5):705.
Score: 0.052
-
Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.
Score: 0.052
-
Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.
Score: 0.051
-
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 04; 35(4):470-479.
Score: 0.051
-
Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
Score: 0.051
-
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
Score: 0.049
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.048
-
Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
Score: 0.047
-
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
Score: 0.047
-
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/S?zary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom. 2021 03; 100(2):183-191.
Score: 0.046
-
Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget. 2020 Feb 11; 11(6):600-618.
Score: 0.045
-
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.
Score: 0.044
-
Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res. 2019 11; 86:106227.
Score: 0.044
-
Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones). Cytometry B Clin Cytom. 2020 01; 98(1):36-42.
Score: 0.043
-
TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
Score: 0.043
-
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
Score: 0.041
-
Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One. 2018; 13(9):e0204218.
Score: 0.041
-
Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
Score: 0.040
-
Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018 07; 70:97-99.
Score: 0.040
-
Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018 07 01; 124(13):2704-2713.
Score: 0.039
-
Fifteen-Year Journey to High Reliability in Pathology and Laboratory Medicine. Am J Med Qual. 2018 Sep/Oct; 33(5):530-539.
Score: 0.039
-
MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget. 2018 Feb 27; 9(16):12959-12970.
Score: 0.039
-
Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.
Score: 0.039
-
Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271.
Score: 0.038
-
Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.
Score: 0.038
-
Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12(8):e0181968.
Score: 0.038
-
Characterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 Aug; 92(8):E175-E177.
Score: 0.037
-
Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.
Score: 0.037
-
Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet. 2017 04; 212-213:24-31.
Score: 0.037
-
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.
Score: 0.036
-
Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.
Score: 0.036
-
A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.
Score: 0.036
-
Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn. 2016 09; 18(5):676-687.
Score: 0.035
-
Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. J Clin Pathol. 2016 Apr 15.
Score: 0.034
-
Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016 Mar 22; 7(12):14251-8.
Score: 0.034
-
Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.
Score: 0.033
-
Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
Score: 0.033
-
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
Score: 0.032
-
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76.
Score: 0.032
-
The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015 Jun; 90(6):504-10.
Score: 0.032
-
Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015 Apr; 39(4):454-61.
Score: 0.032
-
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
Score: 0.031
-
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014 Nov 11; 111(10):2014-23.
Score: 0.031
-
Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
Score: 0.031
-
Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014 Apr; 141(4):559-72.
Score: 0.030
-
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.
Score: 0.030
-
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.
Score: 0.029
-
TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.
Score: 0.029
-
Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb; 27(2):314-27.
Score: 0.029
-
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013 Sep; 15(5):607-22.
Score: 0.028
-
Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol. 2013 Oct; 26(10):1338-45.
Score: 0.028
-
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis. 2009 Apr; 14(4):336-47.
Score: 0.021
-
High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood. 2006 Sep 01; 108(5):1783-4.
Score: 0.018